Next Article in Journal
Management of Castration-Resistant Prostate Cancer: A Global Approach
Previous Article in Journal
Androgen Deprivation Therapy in Advanced Prostate Cancer: Is Intermittent Therapy the New Standard of Care?
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Review

Targeting the Androgen Receptor in the Management of Castration-Resistant Prostate Cancer: Rationale, Progress, and Future Directions

Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(s1), 22-31; https://doi.org/10.3747/co.19.1281
Received: 6 September 2012 / Revised: 4 October 2012 / Accepted: 2 November 2012 / Published: 1 December 2012
Since the year 2000, tremendous progress has been made in the understanding of castration-resistant prostate cancer (CRPC), a disease state now recognized to retain androgen receptor (AR)—dependency in most cases. That understanding led to the rational design of novel therapeutic agents targeting hormonal pathways in metastatic crpc. Two new drugs—the CYP17 inhibitor abiraterone acetate and the potent AR antagonist enzalutamide—were recently shown to prolong overall survival after chemotherapy treatment in patients with metastatic disease, with the former agent also demonstrating impressive activity in the pre-chemotherapy setting. Other new drugs targeting the AR—as well as drugs targeting heat shock proteins that protect cytoplasmic AR from degradation—are currently undergoing clinical development. This review brief ly describes the molecular mechanisms underlying castration resistance and hormonal dependence in prostate tumours and summarizes the current ongoing and completed clinical trials that are targeting hormonal pathways in metastatic crpc. Potential mechanisms of resistance to these novel hormonal agents are reviewed. Finally, future research directions, including questions about drug sequencing and combination, are discussed.
Keywords: prostate; androgen; castration; bicalutamide; abiraterone; enzalutamide; orteronel; galeterone; CYP17; ARN-509; ODM-201 prostate; androgen; castration; bicalutamide; abiraterone; enzalutamide; orteronel; galeterone; CYP17; ARN-509; ODM-201
MDPI and ACS Style

Leibowitz–Amit, R.; Joshua, A.M. Targeting the Androgen Receptor in the Management of Castration-Resistant Prostate Cancer: Rationale, Progress, and Future Directions. Curr. Oncol. 2012, 19, 22-31. https://doi.org/10.3747/co.19.1281

AMA Style

Leibowitz–Amit R, Joshua AM. Targeting the Androgen Receptor in the Management of Castration-Resistant Prostate Cancer: Rationale, Progress, and Future Directions. Current Oncology. 2012; 19(s1):22-31. https://doi.org/10.3747/co.19.1281

Chicago/Turabian Style

Leibowitz–Amit, R., and A.M. Joshua. 2012. "Targeting the Androgen Receptor in the Management of Castration-Resistant Prostate Cancer: Rationale, Progress, and Future Directions" Current Oncology 19, no. s1: 22-31. https://doi.org/10.3747/co.19.1281

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop